The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 2 · 500 people · 165 sites in 19 countries · Recruiting now

August 11, 2026
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Phase 2 · 34 people · 1 site in China · Recruiting now

August 11, 2026
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Phase 2 · 167 people · 4 sites in United Kingdom · Recruiting now

August 11, 2026
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 2 · 147 people · 21 sites in United States · Recruiting now

August 11, 2026
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Phase 2 · randomised · 62 people · 1 site in China · Recruiting now

August 11, 2026
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 2 · randomised · 499 people · 3 sites in United States · Recruiting now

August 11, 2026
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2

Phase 2 · 111 people · 54 sites in 11 countries · Recruiting now

August 11, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Phase 2 · 178 people · 1 site in China · Recruiting now

August 11, 2026
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Phase 2 · 265 people · 16 sites in 2 countries · Recruiting now

August 11, 2026
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

Phase 2 · 17 people · 1 site in United States · Recruiting now

August 11, 2026